NCT07527325 is a Phase 2 clinical trial of Fianlimab in Melanoma (Skin), sponsored by University of California, Irvine.

Who is sponsoring NCT07527325?

NCT07527325 is sponsored by University of California, Irvine.

What drugs are being tested in NCT07527325?

Interventions in NCT07527325: Fianlimab, Cemiplimab.

What condition does NCT07527325 study?

NCT07527325 studies Melanoma (Skin).

Is NCT07527325 still recruiting?

NCT07527325 is currently not yet recruiting. Last updated 14 April 2026.

Last reviewed 2026-04-14 · How we verify

NCT07527325

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

Not yet recruiting Phase 2 Last updated 14 April 2026

What this trial tests

Phase 2 trial testing Fianlimab in Melanoma (Skin) in 35 participants. Not yet recruiting.

Timeline

30 April 2026

Primary endpoint
1 February 2029

1 February 2030

Quick facts

Lead sponsor	University of California, Irvine
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	30 April 2026
Primary completion	1 February 2029
Estimated completion	1 February 2030
Sites	1 location across United States

Drugs / interventions tested

Fianlimab — full drug profile →
Cemiplimab (CEMIPLIMAB) — full drug profile →

Conditions studied

Melanoma (Skin) — all drugs for Melanoma (Skin) →

Sponsor

University of California, Irvine

Who can join

Eligibility, any sex, with Melanoma (Skin). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Fianlimab

Trials testing the same drug.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07511036 — PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patie · Phase 2 · not yet recruiting
NCT06787612 — Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer · Phase 2 · recruiting
NCT06918132 — Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer · Phase 2 · recruiting
NCT06161441 — A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combina · Phase 2 · active not recruiting

Other recruiting trials for Melanoma (Skin)

Currently open trials in the same condition.

NCT06643286 — Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma · NA · recruiting
NCT06298734 — High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial · NA · recruiting
NCT05704647 — Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases · Phase 2 · recruiting
NCT05492682 — START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer · Phase 1 · active not recruiting
NCT05649683 — Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors · NA · recruiting

Other University of California, Irvine trials

Trials by the same sponsor.

NCT06952725 — Chatbot for Online Support Groups to Treat Tobacco Addiction · NA · not yet recruiting
NCT07167862 — Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound · Phase 4 · not yet recruiting
NCT07391891 — Musical Mindfulness for Pain in the ED Waiting Room · NA · not yet recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07527325 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Irvine
Last refreshed: 14 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07527325.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing